Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)

NCT03354962 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Slow recruitment rate

Conditions

Melanoma

Interventions

COMBINATION_PRODUCT: Nivolumab + Ipilimumab
COMBINATION_PRODUCT: Combined treatment schema

Sponsor

Institut Claudius Regaud